HilleVax

HilleVax was a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, most notably HIL-214, a virus-like-particle based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was surfaced in the API Evangelist network as a portfolio company of Lightspeed Venture Partners. Enrichment probing found no developer program, no API, no developer portal, and no public API documentation of any kind, which is expected for a clinical-stage vaccine developer rather than a technology/API producer. The company's primary domain (hillevax.com) now redirects to xoma.com (XOMA Royalty), indicating HilleVax has been acquired and wound down as an independent operating company; XOMA Royalty itself was subsequently acquired by Ligand (closed July 2026). This profile is retained as a company/identity record with no API surface.

HilleVax is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Vaccines, Life Sciences, and Healthcare.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyBiopharmaceuticalVaccinesLife SciencesHealthcareNorovirusClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/hillevax: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: hillevax
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/hillevax.png
name: HilleVax
description: HilleVax was a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines,
  most notably HIL-214, a virus-like-particle based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis
  caused by norovirus infection. The company was surfaced in the API Evangelist network as a portfolio company of Lightspeed
  Venture Partners. Enrichment probing found no developer program, no API, no developer portal, and no public API documentation
  of any kind, which is expected for a clinical-stage vaccine developer rather than a technology/API producer. The company's
  primary domain (hillevax.com) now redirects to xoma.com (XOMA Royalty), indicating HilleVax has been acquired and wound
  down as an independent operating company; XOMA Royalty itself was subsequently acquired by Ligand (closed July 2026). This
  profile is retained as a company/identity record with no API surface.
url: https://raw.githubusercontent.com/api-evangelist/hillevax/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: no-api-surface
x-status: acquired
x-acquisition-note: hillevax.com redirects to xoma.com (XOMA Royalty); no developer/API surface exists.
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Vaccines
- Life Sciences
- Healthcare
- Norovirus
- Clinical Stage
common:
- type: Website
  url: https://www.hillevax.com
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1